Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy

Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy

Abstract Immune checkpoint inhibitors (ICIs) such as anti-PD-L1 antibodies are widely used to treat human cancers, and growing evidence suggests that ICIs are promising treatments for canine malignancies. However, only some canine oral malignant melanoma (OMM) cases respond to ICIs. To explore bioma...

Full description

Bibliographic Details
Main Authors: Naoya Maekawa, Satoru Konnai, Yumie Asano, Yamato Sajiki, Tatsuya Deguchi, Tomohiro Okagawa, Kei Watari, Hiroto Takeuchi, Satoshi Takagi, Kenji Hosoya, Sangho Kim, Hiroshi Ohta, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata, Kazuhiko Ohashi
Format: Article
Language:English
Published: Nature Portfolio 2022-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-13484-8

Internet

https://doi.org/10.1038/s41598-022-13484-8

Similar Items